RECRUITING

Validation of i-ROP DL to Detect More Than Mild ROP

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the pivotal reader study is to assess the readers' accuracy in diagnosing plus disease versus no plus or pre-plus disease with or without the aid of the i-ROP DL. Ophthalmologists' performance metrics for the following modalities will be evaluated: * Standard evaluation following the standard of care process ("without i-ROP DL") * Evaluation following the standard of care process with the aid of the i-ROP DL ("with i-ROP DL") This retrospective multi-reader multi-case (MRMC) study will have an enriched sample of approximately 300 eye cases (1 study eye per subject): 60 plus cases, 120 pre-plus cases and 120 no plus cases. Enrichment is with respect to proportions of plus cases and pre-plus cases. The primary objective of this study is to evaluate whether the area under the receiver operating characteristic (ROC) curve (AUC) based on probability scores of plus disease statistically significantly non-inferior or superior with the aid of the i-ROP DL versus without the aid of the i-ROP DL. Multiple secondary endpoints are outlined in the next section.

Official Title

Validation of i-ROP DL to Detect More Than Mild Retinopathy of Prematurity and a Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of Diagnosing Plus Disease of Premature Infants With or Without the Aid of the i-ROP DL in Telemedicine Setting

Quick Facts

Study Start:2024-06-25
Study Completion:2025-03-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06109285

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:20 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * U.S. board-eligible/board-certified and licensed Medical Doctor, Doctor of Ophthalmology. (American Board of Ophthalmology or equivalent certification)
  2. * Signed reader study agreement.
  3. * Signed informed consent.
  4. * Successful training on the study protocol and the use of the study software
  1. * Did not sign reader study agreement.
  2. * Did not sign informed consent.
  3. * Did not successfully complete training on the study protocol and the use of the study software

Contacts and Locations

Study Contact

Karyn E Jonas, MSN
CONTACT
5618182161
karyn@siloamvision.com
Susan Ostmo, MS
CONTACT
ostmo@ohsu.edu

Principal Investigator

John P Campbell, MD/MPH
PRINCIPAL_INVESTIGATOR
Oregon Health and Science University

Study Locations (Sites)

Oregon Health and Sciences University
Portland, Oregon, 97239
United States

Collaborators and Investigators

Sponsor: Siloam Vision

  • John P Campbell, MD/MPH, PRINCIPAL_INVESTIGATOR, Oregon Health and Science University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-25
Study Completion Date2025-03-01

Study Record Updates

Study Start Date2024-06-25
Study Completion Date2025-03-01

Terms related to this study

Keywords Provided by Researchers

  • Retinopathy of Prematurity
  • ROP

Additional Relevant MeSH Terms

  • Retinopathy of Prematurity
  • ROP